<DOC>
	<DOCNO>NCT00003389</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining one drug radiation therapy may kill cancer cell . It yet know combination chemotherapy regimen effective treat Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study two different combination chemotherapy regimens compare well work , without radiation therapy , treat patient Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Radiation Therapy Treating Patients With Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare failure-free survival patient locally extensive advance Hodgkin 's lymphoma treat doxorubicin , bleomycin , vinblastine , dacarbazine ( ABVD ) v doxorubicin , vinblastine , vincristine , bleomycin , mechlorethamine , etoposide , prednisone ( Stanford V ) without radiotherapy . - Compare overall survival freedom progression patient 5 10 year treatment regimens . - Compare pulmonary function , incidence second cancer , reproductive function , deaths cause Hodgkin 's lymphoma patient treat regimen . OUTLINE : This randomize study . Patients stratify accord number adverse risk factor ( 0-2 v 3-7 ) , disease characteristic ( locally extensive v advance ) time entry ( addendum 6 vs. addendum 6 ) . Patients randomize 1 2 treatment arm . - Arm A ( ABVD ) : Patients receive doxorubicin ( 25 mg/m² ) , bleomycin ( 10 u/m² ) , vinblastine ( 6 mg/m² ) , dacarbazine ( 375 mg/m² ) IV day 1 15 . Courses repeat every 28 day . Patients restaged 4 course . Patients complete remission receive 2 additional course . Patients partial response less evaluated 6 course , ongoing response , patient may receive 2 additional course total 8 . If ongoing response observe , patient remove study . All patient massive mediastinal disease , regardless stage , receive radiotherapy 2-3 week completion chemotherapy . - Arm B ( Stanford V ) : Patients receive Stanford V chemotherapy comprise doxorubicin ( 25 mg/m² ) vinblastine ( 6 mg/m² ) IV day 1 week 1 , 3 , 5 , 7 , 9 , 11 ; vincristine ( 1.4 mg/m² ) bleomycin ( 5 u/m² ) IV day 1 week 2 , 4 , 6 , 8 , 10 , 12 ; mechlorethamine ( 6 mg/m² ) IV day 1 week 1 , 5 , 9 ( mechlorethamine unavailable , may substitute cyclophosphamide [ 375 mg/m² ] IV ) ; etoposide ( 60 mg/m² ) IV day 1 2 week 3 , 7 , 11 ; oral prednisone ( 40 mg/m² ) every day week 1-9 follow taper . All patient bulky disease receive radiotherapy 2-3 week completion chemotherapy . Patients follow every 2 month 1 year , every 3 month 1 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 850 patient accrue study within 4.3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mechlorethamine</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Imidazole</mesh_term>
	<criteria>Inclusion criterion : Histologically prove previously untreated classical Hodgkin 's lymphoma The following stage eligible : Locally extensive : Stage IIIA/B massive mediastinal adenopathy Advanced : Stage III IV Measurable evaluable disease Age 16 ECOG Performance status 02 Diseasefree prior invasive malignancy &gt; 5 year exception curativelytreated basal cell squamous cell carcinoma skin carcinoma situ cervix White blood cell ( WBC ) least 4,000/mm³ , ( unless document bone marrow involvement ) Platelet count least 100,000/mm³ ( unless document bone marrow involvement ) Bilirubin great 5.0 mg/dL Creatinine great 2.0 mg/dL Ejection fraction determination recommend age 50 and/or history cardiac disease Fertile patient must use effective contraception Prior corticosteroid allow Prior surgery allow Exclusion criterion : Pregnant nursing Prior radiotherapy Prior chemotherapy Human immunodeficiency virus ( HIV ) positive</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>adult lymphocyte depletion Hodgkin lymphoma</keyword>
	<keyword>adult nodular sclerosis Hodgkin lymphoma</keyword>
	<keyword>adult mixed cellularity Hodgkin lymphoma</keyword>
</DOC>